Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022165039 - ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF

Publication Number WO/2022/165039
Publication Date 04.08.2022
International Application No. PCT/US2022/014103
International Filing Date 27.01.2022
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
22from camelids, e.g. camel, llama or dromedary
Applicants
  • TALEM THERAPEUTICS LLC [US]/[US]
Inventors
  • ROODINK, Ilse
  • ABDICHE, Yasmina Noubia
  • BATH, Jennifer L.
Agents
  • TEAGUE, Meghann K.
  • MAYER, Mika R.
  • BOLIN, Kimberly A.
Priority Data
63/142,78728.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF
(FR) ANTICORPS ANTI-GLYCOPROTÉINE ANTI-SPICULE DE SARS-COV-2 ET LEUR UTILISATION THÉRAPEUTIQUE
Abstract
(EN) The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
(FR) La présente invention concerne des anticorps neutralisants ou des fragments de liaison à l'antigène de ceux-ci contre des bêta-coronavirus tels que le coronavirus du syndrome respiratoire aigu sévère 2 (SARS-CoV-2), au moins un acide nucléique codant de tels anticorps neutralisants ou des fragments de liaison à l'antigène de ceux-ci, et un mélange et des compositions comprenant de tels anticorps, fragments de liaison à l'antigène ou acides nucléiques. De tels anticorps neutralisants ou des fragments de liaison à l'antigène de ceux-ci peuvent bloquer l'entrée de bêta-coronavirus dans des cellules et/ou induire une cytotoxicité dépendante du complément (CDC), la cytotoxicité cellulaire dépendante des anticorps (ADCC) et/ou la phagocytose cellulaire dépendante des anticorps (ADCP) contre les cellules infectées par le bêta-coronavirus. L'invention concerne également des méthodes et des utilisations des anticorps, des fragments de liaison à l'antigène de ceux-ci, au moins un acide nucléique ou des compositions, y compris des méthodes thérapeutiques, diagnostiques et préventives et des utilisations pour des infections à bêta-coronavirus et des maladies associées telles que la COVID-19.
Latest bibliographic data on file with the International Bureau